An Oral, Selective Tyrosine Kinase 2 Inhibitor, BMS-986165, Reduced Absolute Psoriasis Area and Severity Index in a Phase 2 Trial in Psoriasis. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 4, n. 5, p. s27, 2020. DOI: 10.25251/skin.4.supp.27. Disponível em: https://skin.dermsquared.com/skin/article/view/976. Acesso em: 19 apr. 2025.